Corbus Pharmaceuticals Reports $23.3 Million Net Loss in Q3 2025, Driven by Increased R&D Expenses

Corbus Pharmaceuticals Holdings, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $23.3 million for the third quarter, compared to a loss of $13.8 million in the same period last year, marking an increase of 69% year-over-year. For the nine months ended September 30, 2025, the net loss was approximately $58.0 million, up from $30.7 million in the prior year. The increase in losses is attributed primarily to heightened research and development expenses, which surged by 93% to $20.9 million in the third quarter, driven by costs associated with ongoing clinical trials for its product candidates.

Total operating expenses for the third quarter reached $24.4 million, a 57% increase from $15.5 million in the same quarter of 2024. Research and development expenses accounted for the majority of this increase, reflecting the company's commitment to advancing its clinical pipeline, which includes CRB-701, CRB-601, and CRB-913. The company’s general and administrative expenses decreased by 24% to $3.6 million, primarily due to reduced compensation costs and lower investor relations expenses. As of September 30, 2025, Corbus reported total current assets of approximately $107.6 million, down from $153.0 million at the end of 2024, while current liabilities increased to $17.1 million from $11.8 million.

In terms of strategic developments, Corbus has been actively pursuing its clinical programs. The company is currently conducting Phase 1/2 clinical trials for CRB-701 and CRB-601, with the latter having commenced dosing in December 2024. The company also initiated a Phase 1 study for CRB-913 in early 2025. Corbus has expanded its clinical trial sites in Europe and is collaborating with CSPC Megalith Biopharmaceutical Co. Ltd. for the development of CRB-701. The company’s employee headcount has increased, contributing to higher personnel-related costs, which rose by 51% in the third quarter compared to the previous year.

Corbus has also engaged in capital-raising activities, selling 272,938 shares of common stock under its Open Market Sale Agreement, generating approximately $2.9 million in net proceeds. The company anticipates that its cash, cash equivalents, and investments of approximately $104.0 million as of September 30, 2025, along with additional proceeds from recent offerings, will be sufficient to meet its operational needs for at least the next twelve months. However, the company acknowledges the necessity of raising further capital to support ongoing clinical trials and operational expenses, emphasizing the uncertainty surrounding future funding availability.

Looking ahead, Corbus remains focused on advancing its clinical programs while managing its financial resources prudently. The company expects to continue incurring significant operating losses as it progresses through its clinical development phases. The outlook remains contingent on the successful completion of clinical trials and the ability to secure additional financing, which may include public or private equity offerings, debt financing, or collaborations with third parties.